# Septerna, Inc. Common Stock (SEPN)

> Septerna, Inc. Common Stock (SEPN) trades at $42.60 (+1.77%) as of 7:30:02 PM EST on Nov 13, 2026, +13.75% over the past month. Market cap is $2.03B, with 11.9 days to cover in short interest.

Canonical: https://massive.com/quote/sepn
Data as of: 2026-11-14T00:30:02.143Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$42.60** +0.74 (+1.77%)
As of 7:30:02 PM EST on Nov 13, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Septerna, Inc. Common Stock (SEPN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +1.77% |
| 1W | -12.79% |
| 1M | +13.75% |
| YTD | +52.80% |
| 1Y | +96.86% |
| 52-wk range | $21.31 – $53.34 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for SEPN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $40.60 – $42.88 |
| Open | $41.27 |
| Prev close | $41.86 |
| Volume | 337.79K |
| Market cap | $2.03B |
| Shares out | 47.55M |

## Valuation and profitability ratios

Valuation and profitability ratios for Septerna, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 21.04 |
| P/B | 4.73 |
| P/FCF | — |
| ROE | -13.8% |
| ROA | -9.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[Septerna, Inc. Common Stock (SEPN) insider trading](https://massive.com/quote/sepn/insider-trading.md): open-market Form 4 buys and sells by Septerna, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Septerna, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 09, 2026, Septerna, Inc. (the "Company") announced its financial results and business highlights for the quarter ended September 30, 2026.”
- Nov 4, 2026 · Business update
  “On November 4, 2026, Septerna, Inc. issued a press release titled "Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting."”
- Aug 25, 2026 · Executive officer appointment
  “Effective August 24, 2026, the Company's Board of Directors appointed Rajiv Patni, M.D., as the Company's Chief Medical Officer.”
- Jun 30, 2026 · Annual meeting results
  “The Company's stockholders elected Shalini Sharp, M.B.A. and Jake Simson, Ph.D. to the Company's Board of Directors (the "Board") as Class II directors, each for a three-year term ending at the annual meeting of stockholders of the Company to be held in 2029. The results of the stockholders' vote with respect to the election of the Class II directors were as follows: \[vote tallies provided\].”
- Apr 13, 2026 · Investor presentation
  “The Company also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.”

## SEPN short interest

How heavily SEPN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 11.9 |
| Short interest | 3.35M |
| Avg volume | 280.56K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## SEPN news

The latest news and headlines about Septerna, Inc. Common Stock (SEPN).

- [Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates](https://www.zacks.com/stock/news/3026761/septerna-inc-sepn-reports-q3-loss-lags-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3026761) · Zacks Investment Research · Nov 9, 2026 · negative sentiment
- [Moderna (MRNA) Q3 Earnings and Revenues Top Estimates](https://www.zacks.com/stock/news/3025255/moderna-mrna-q3-earnings-and-revenues-top-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025255) · Zacks Investment Research · Nov 6, 2026 · positive sentiment
- [Puma Biotech (PBYI) Tops Q3 Earnings Estimates](https://www.zacks.com/stock/news/3025027/puma-biotech-pbyi-tops-q3-earnings-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3025027) · Zacks Investment Research · Nov 5, 2026 · neutral sentiment
- [Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/09/10/3359956/0/en/septerna-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html) · GlobeNewswire Inc. · Sep 10, 2026 · positive sentiment
- [Septerna to Participate in Upcoming Investor Conferences](https://www.globenewswire.com/news-release/2026/09/01/3354043/0/en/septerna-to-participate-in-upcoming-investor-conferences.html) · GlobeNewswire Inc. · Sep 1, 2026 · positive sentiment

## About Septerna, Inc. Common Stock

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Listed | Oct 25, 2024 |

[Company website](https://www.septerna.com)

## FAQ

### What is the Septerna, Inc. Common Stock (SEPN) stock price today?

Septerna, Inc. Common Stock (SEPN) is trading at $42.60 (+1.77% on the day) as of 7:30:02 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Septerna, Inc. Common Stock?

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform.

### What is the short interest in SEPN?

As of Oct 30, 2026, SEPN has 3.35M shares short and 11.9 days to cover.

### What exchange is SEPN listed on?

Septerna, Inc. Common Stock (SEPN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time SEPN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=SEPN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Septerna, Inc. Common Stock (SEPN) insider trading](https://massive.com/quote/sepn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
